Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


State ADAPs secure higher Rx discounts

Executive Summary

Abbott, Boehringer Ingelheim, Gilead and Merck agree to price concessions for state AIDS drug assistance programs. Abbott agreement provides supplemental rebates on full HIV/AIDS product line; BI says it will freeze Viramune price for two years. Companies join Roche in finalizing negotiations following Washington, D.C. meeting (1"The Pink Sheet" April 21, p. 7). Discussions with Pfizer/Agouron, GlaxoSmithKline and Bristol-Myers Squibb are ongoing, state directors say...

You may also be interested in...

Bristol at impasse with ADAPs

Negotiations between Bristol-Myers Squibb and coalition of state AIDS Drug Assistance Program directors has "stalled," Treatment Action Group Representative Robert Camp says during Bristol Reyataz advisory committee meeting. "I am here to express profound disappointment at BMS' failure to negotiate serious price discounts and freezes in good faith with state and territorial ADAP directors." Bristol is one of three HIV therapy manufacturers who has not yet reached an agreement with the state AIDS program; other companies include Pfizer/Agouron and GlaxoSmithKline (1"The Pink Sheet" April 28, In Brief)...

State ADAPs Ask Manufacturers For Price Concessions; Fuzeon Fuels Effort

State AIDS Drug Assistance Programs are asking all HIV therapy manufacturers for price breaks as they prepare to pick up coverage of Roche's Fuzeon

US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques

The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts